News stories about Rosetta Genomics (NASDAQ:ROSG) have been trending very positive on Friday, according to Accern Sentiment. Accern identifies negative and positive news coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Rosetta Genomics earned a news impact score of 0.56 on Accern’s scale. Accern also gave media headlines about the medical research company an impact score of 0 out of 100, meaning that recent news coverage is extremely unlikely to have an effect on the company’s share price in the next several days.
Shares of Rosetta Genomics (ROSG) traded up 4.29% on Friday, reaching $1.70. 46,766 shares of the company traded hands. The stock’s 50 day moving average price is $2.11 and its 200-day moving average price is $3.23. The stock’s market capitalization is $3.18 million. Rosetta Genomics has a one year low of $1.40 and a one year high of $13.20.
About Rosetta Genomics
Rosetta Genomics Ltd. is engaged in developing and commercializing new diagnostic tests based on various genomics markers, including deoxyribonucleic acid (DNA), micro ribonucleic acid (microRNA) and protein biomarkers and using various technologies, including, Quantitative polymerase chain reaction (qPCR), microarrays, Next Generation Sequencing (NGS) and Fluorescence In Situ Hybridization (FISH).
What are top analysts saying about Rosetta Genomics Ltd.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Rosetta Genomics Ltd. and related companies.